

# Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement

Information for the public

Published: 11 September 2024

[www.nice.org.uk](http://www.nice.org.uk)

Futibatinib (Lytgobi) is available on the NHS. It is a possible treatment for bile duct cancer (cholangiocarcinoma) in adults that has:

- spread nearby the bile duct (locally advanced) or to other parts of the body (metastatic)
- a fibroblast growth factor receptor 2 (FGFR2) gene mutation (fusion or rearrangement)
- got worse (progressed) after at least 1 line of systemic treatment.

Systemic treatments are medicines that work throughout the whole body. They can include injections, infusions or medicines taken by mouth.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

The [NHS webpage on bile duct cancer](#) may be a good place to find out more.

[AMMF – The Cholangiocarcinoma Charity](#), 01279 661479, can give you advice and support.

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-6126-9